Reversal of diabetic vasculopathy in a rat model of type 1 diabetes by opiorphin-related peptides

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 301, Issue 4, 2011, Pages

  Calenda, Giulia ^a   Tong, Yuehong ^a   Kanika, Nirmala D ^a   Tar, Moses T ^a   Suadicani, Sylvia O ^a   Zhang, Xinhua ^c   Melman, Arnold ^a   Rougeot, Catherine ^b   Davies, Kelvin P ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b INSTITUT PASTEUR   (France)

^c NONE

Author keywords

Erectile dysfunction; Hypertension; Sialorphin

Indexed keywords

BRADYKININ; CALCIUM; NATRIURETIC PEPTIDE RECEPTOR C; PROTEIN; SIALORPHIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA MEDIA; ARTICLE; BLOOD PRESSURE; CALCIUM CELL LEVEL; CONTROLLED STUDY; DIABETIC ANGIOPATHY; ERECTILE DYSFUNCTION; GENE EXPRESSION; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MUSCLE RELAXATION; NONHUMAN; PLASMID; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA, THORACIC; BLOOD PRESSURE; BRADYKININ; CALCIUM; CALCIUM SIGNALING; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; GENE TRANSFER TECHNIQUES; MUSCLE, SMOOTH, VASCULAR; NATRIURETIC PEPTIDE, C-TYPE; OLIGOPEPTIDES; PENILE ERECTION; PEPTIDE FRAGMENTS; RATS; RATS, INBRED F344; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SALIVARY PROTEINS AND PEPTIDES;

EID: 80053235841     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00383.2011     Document Type: Article

References (48)

1. Archer SL. Potassium channels and erectile dysfunction. Vascul Pharmacol 38: 61-71, 2002.
2. Burnett AL. Erectile dysfunction. J Urol 175: S25-31, 2006.
3. Calenda G, Suadicani SO, Iglesias R, Spray DC, Melman A, Davies KP. Silencing MaxiK activity in corporal smooth muscle cells initiates compensatory mechanisms to maintain calcium homeostasis. J Sex Med 8: 2191-2204, 2011.
4. Calenda G, Tong Y, Tar M, Lowe D, Siragusa J, Melman A, Davies KP. Vcsa1 acts as a marker of erectile function recovery after gene therapeutic and pharmacological interventions. J Urol 181: 2806-2815, 2009.
5. Campese VM, Lasseter KC, Ferrario CM, Smith WB, Ruddy MC, Grim CE, Smith RD, Vargas R, Habashy MF, Vesterqvist O, Delaney CL, Liao WC. Omapatrilat vs. lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients. Hypertension 38: 1342-1348, 2001.
6. Chen S, Yuan CM, Haddy FJ, Pamnani MB. Effect of administration of insulin on streptozotocin-induced diabetic hypertension in rat. Hypertension 23: 1046-1050, 1994.
7. Christ GJ, Day N, Santizo C, Sato Y, Zhao W, Sclafani T, Bakal R, Salman M, Davies K, Melman A. Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo. Am J Physiol Heart Circ Physiol 287: H1544-H1553, 2004.
8. Christ GJ, Rehman J, Day N, Salkoff L, Valcic M, Melman A, Geliebter J. Intracorporal injection of hSlo cDNA in rats produces physiologically relevant alterations in penile function. Am J Physiol Heart Circ Physiol 275: H600-H608, 1998.
9. Cooper ME, Bonnet F, Oldfield M, Jandeleit-Dahm K. Mechanisms of diabetic vasculopathy: an overview. Am J Hypertens 14: 475-486, 2001.
10. Davies KP, Tar M, Rougeot C, Melman A. Sialorphin (the mature peptide product of Vcsa1) relaxes corporal smooth muscle tissue and increases erectile function in the ageing rat. BJU Int 99: 431-435, 2007.
11. Dery RE, Ulanova M, Puttagunta L, Stenton GR, James D, Merani S, Mathison R, Davison J, Befus AD. Frontline: inhibition of allergeninduced pulmonary inflammation by the tripeptide feG: a mimetic of a neuro-endocrine pathway. Eur J Immunol 34: 3315-3325, 2004.
12. Eaton CB, Liu YL, Mittleman MA, Miner M, Glasser DB, Rimm EB. A retrospective study of the relationship between biomarkers of atherosclerosis and erectile dysfunction in 988 men. Int J Impot Res 19: 218-225, 2007.
13. Favrat B, Burnier M, Nussberger J, Lecomte JM, Brouard R, Waeber B, Brunner HR. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J Hypertens 13: 797-804, 1995.
14. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151: 54-61, 1994.
15. Grover VS, Sharma A, Singh M. Role of nitric oxide in diabetes-induced attenuation of antinociceptive effect of morphine in mice. Eur J Pharmacol 399: 161-164, 2000.
16. Kanika ND, Tar M, Tong Y, Kuppam DS, Melman A, Davies KP. The mechanism of opiorphin-induced experimental priapism in rats involves activation of the polyamine synthetic pathway. Am J Physiol Cell Physiol 297: C916-C927, 2009.
17. Karicheti V, Santizo C, Zhao W, Kuo E, Shenk G, Melman A, Christ GJ. Changes in electrical properties of detrusor smooth muscle in the STZ (streptozotocin)-diabetic rat. Urology 57: 110-111, 2001.
18. Kirby M, Jackson G, Simonsen U. Endothelial dysfunction links erectile dysfunction to heart disease. Int J Clin Pract 59: 225-229, 2005.
19. Kupelian V, Shabsigh R, Araujo AB, O'Donnell AB, McKinlay JB. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J Urol 176: 222-226, 2006.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2[-delta delta C(T)] method. Methods 25: 402-408, 2001.
21. Marton Z, Pataricza J, Krassoi I, Varro A, Papp JG. NEP inhibitors enhance C-type natriuretic peptide-induced relaxation in porcine isolated coronary artery. Vascul Pharmacol 43: 207-212, 2005.
22. Mathison RD, Befus AD, Davison JS. A novel submandibular gland peptide protects against endotoxic and anaphylactic shock. Am J Physiol Regul Integr Comp Physiol 273: R1017-R1023, 1997.
23. Mathison RD, Befus AD, Davison JS. Reduction in cardiovascular anaphylaxis by submandibular gland peptide-T. Proc West Pharmacol Soc 40: 73-74, 1997.
24. McClean DR, Ikram H, Garlick AH, Richards AM, Nicholls MG, Crozier IG. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol 36: 479-486, 2000.
25. Melman A, Bar-Chama N, McCullough A, Davies K, Christ G. hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial. Hum Gene Ther 17: 1165-1176, 2006.
26. Melman A, Rojas L, Christ G. Gene transfer for erectile dysfunction: will this novel therapy be accepted by urologists? Curr Opin Urol 19: 595-600, 2009.
27. Melman A, Zhao W, Davies KP, Bakal R, Christ GJ. The successful long-term treatment of age related erectile dysfunction with hSlo cDNA in rats in vivo. J Urol 170: 285-290, 2003.
28. Morris KE, St Laurent CD, Hoeve RS, Forsythe P, Suresh MR, Mathison RD, Befus AD. Autonomic nervous system regulates secretion of anti-inflammatory prohormone SMR1 from rat salivary glands. Am J Physiol Cell Physiol 296: C514-C524, 2009.
29. Muller A, Mulhall JP. Cardiovascular disease, metabolic syndrome and erectile dysfunction. Curr Opin Urol 16: 435-443, 2006.
30. Parpura V, Basarsky TA, Liu F, Jeftinija K, Jeftinija S, Haydon PG. Glutamate-mediated astrocyte-neuron signalling. Nature 369: 744-747, 1994.
31. Rahman S, Rahman T, Ismail AA, Rashid AR. Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes Metab 9: 767-780, 2007.
32. Ravipati G, McClung JA, Aronow WS, Peterson SJ, Frishman WH. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. Cardiol Rev 15: 76-86, 2007.
33. Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, Connolly V, King H. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 28: 2130-2135, 2005.
34. Roques BP, Noble F, Dauge V, Fournie-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11 structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 45: 87-146, 1993.
35. Rougeot C, Messaoudi M, Hermitte V, Rigault AG, Blisnick T, Dugave C, Desor D, Rougeon F. Sialorphin, a natural inhibitor of rat membrane-bound neutral endopeptidase that displays analgesic activity. Proc Natl Acad Sci USA 100: 8549-8554, 2003.
36. Rougeot C, Rosinski-Chupin I, Njamkepo E, Rougeon F. Selective processing of submandibular rat 1 protein at dibasic cleavage sites. Salivary and bloodstream secretion products. Eur J Biochem 219: 765-773, 1994.
37. Russ RD, Tobin BW. Differential pulmonary vascular effects of streptozotocin diabetes in male and female rats. Proc Soc Exp Biol Med 217: 74-80, 1998.
38. Somani P, Singh HP, Saini RK, Rabinovitch A. Streptozotocin-induced diabetes in the spontaneously hypertensive rat. Metabolism 28: 1075-1077, 1979.
39. Stuckey BG, Walsh JP, Ching HL, Stuckey AW, Palmer NR, Thompson PL, Watts GF. Erectile dysfunction predicts generalised cardiovascular disease: evidence from a case-control study. Atherosclerosis 194: 458-464, 2006.
40. Suadicani SO, Flores CE, Urban-Maldonado M, Beelitz M, Scemes E. Gap junction channels coordinate the propagation of intercellular Ca2 signals generated by P2Y receptor activation. Glia 48: 217-229, 2004.
41. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA 294: 2996-3002, 2005.
42. Tong Y, Tar M, Davelman F, Christ G, Melman A, Davies KP. Variable coding sequence protein A1 as a marker for erectile dysfunction. BJU Int 98: 396-401, 2006.
43. Tong Y, Tar M, Melman A, Davies K. The opiorphin gene (ProL1) and its homologues function in erectile physiology. BJU Int 102: 736-740, 2008.
44. Tong Y, Tar M, Monrose V, DiSanto M, Melman A, Davies KP. hSMR3A as a marker for patients with erectile dysfunction. J Urol 178: 338-343, 2007.
45. Tronik-Le Roux D, Senorale-Pose M, Rougeon F. Three novel SMR1- related cDNAs characterized in the submaxillary gland of mice show extensive evolutionary divergence in the protein coding region. Gene 142: 175-182, 1994.
46. User HM, Zelner DJ, McKenna KE, McVary KT. Microarray analysis and description of SMR1 gene in rat penis in a post-radical prostatectomy model of erectile dysfunction. J Urol 170: 298-301, 2003.
47. Venugopal J. Pharmacological modulation of the natriuretic peptide system. Exp Opin Therapeutic Patents 13: 1389-1409, 2003.
48. Wisner A, Dufour E, Messaoudi M, Nejdi A, Marcel A, Ungeheuer MN, Rougeot C. Human Opiorphin, a natural antinociceptive modulator of opioid-dependent pathways. Proc Natl Acad Sci USA 103: 17979-17984, 2006.